Journal of Alzheimer's Disease 32 (2012) 1–2
IOS Press

Supplementary Data

Postmortem Pittsburgh Compound B (PiB) Binding Increases with Alzheimer's Disease Progression

Tina L. Beckett[a,1], Robin L. Webb[b,1], Dana M. Niedowicz[a,b,1], Christopher J. Holler[b], Sergey Matveev[a,b], Irfan Baig[a,b], Harry LeVine III[a,b,*], Jeffrey N. Keller[c,*] and M. Paul Murphy[a,b,*]
[a]*Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA*
[b]*Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, USA*
[c]*Pennington Biomedical Research Center/Louisiana State University System, Baton Rouge, LA, USA*

Handling Associate Editor: Peter Nelson

Accepted 28 May 2012

Supplementary Table 1
$A\beta_{40}$ and $A\beta_{42}$ values (uncorrected)

	Superior and Middle Temporal Gyri					
	PBS		SDS		FA	
	$A\beta_{40}$	$A\beta_{42}$	$A\beta_{40}$	$A\beta_{42}$	$A\beta_{40}$	$A\beta_{42}$
CON	0.3 ± 0.2	1.3 ± 0.3	4.9 ± 3.1	17.6 ± 9.1	10.1 ± 1.6	24.0 ± 19.2
PCAD	0.3 ± 0.1	1.6 ± 0.2	2.6 ± 0.9	19.8 ± 6.3	13.0 ± 1.3	44.0 ± 20.6
MCI	0.4 ± 0.1	1.2 ± 0.5	3.1 ± 0.6	16.0 ± 6.1	27.3 ± 4.1	116 ± 82.4
AD	0.6 ± 0.3	2.0 ± 0.3	111 ± 52.5*	1032 ± 131*	310 ± 108.3*	98.7 ± 16.5
FTD	0.3 ± 0.1	1.3 ± 0.6	3.1 ± 0.7	0.0 ± 0.0	18.0 ± 1.5	18.3 ± 19.2
				Cerebellum		
CON	0.2 ± 0.0	2.1 ± 0.2	7.9 ± 1.6	0.7 ± 0.7	12.2 ± 1.3	2.5 ± 2.5
PCAD	0.2 ± 0.1	1.6 ± 0.3	11.4 ± 0.9	0.2 ± 0.2	13.4 ± 1.2	2.2 ± 1.5
MCI	0.0 ± 0.0	0.8 ± 0.3	11.1 ± 0.9	1.2 ± 1.0	14.8 ± 3.0	0.0 ± 0.0
AD	0.4 ± 0.2	1.2 ± 0.3	53.8 ± 28.8	62.0 ± 5.3*	544 ± 328.7	87.9 ± 37.6*
FTD	0.0 ± 0.0	1.4 ± 0.1	7.3 ± 1.4	0.0 ± 0.0	9.0 ± 0.9	0.2 ± 0.2

Values are given in pmol/g (see main text for a description of the methods). *$p < 0.05$, Dunnett's test (relative to control group). AD, Alzheimer's disease; Aβ, amyloid-β; CON, control; FA, formic acid; FTD, frontotemporal dementia; MCI, mild cognitive impairment; PBS, phosphate buffered saline; PCAD; preclinical Alzheimer's disease; SDS, sodium dodecyl sulfate.

[1]These authors contributed equally to this work.

*Correspondence to: Dr. M. Paul Murphy, 211 Sanders-Brown Center on Aging, 800 S. Limestone, Lexington, KY 40536-0230, USA. Tel.: +1 859 257 1412; Fax: +1 859 257 9479; E-mail: mpmurp3@email.uky.edu, Dr. Harry LeVine III, 209 Sanders-Brown Center on Aging, 800 S. Limestone, Lexington, KY 40536-0230, USA. Tel.: +1 859 257 1412; Fax: +1 859 323 2866; E-mail: hlevine@email.uky.edu and Dr. Jeffrey N. Keller, Pennington Biomedical Research Center/LSU System, 6400 Perkins Road, Baton Rouge, LA 70808-4124, USA. Tel.: +1 225 763 3190; Fax: +1 225 763 3193; E-mail: jeffrey.keller@pbrc.edu.

ISSN 1387-2877/12/$27.50



Supplementary Figure. 1. As was the case with full length AβPP, levels of β-Actin (Antibody AC15, Sigma-Aldrich; St. Louis, MO) did not vary significantly between cases (*c.f.* corresponding Fig. 2, in main text); this was confirmed by a densitometric analysis (Scion Image; data not shown). All cases in the current cohort are shown from both brain regions. The amount of total protein/lane was identical (SMTG: 90 μg/lane; cerebellum: 50 μg/lane).